President’s Update: BioPharm America 2012, the Most Productive Partnering Event on the East Coast

Hello Readers,

Less than 2 weeks until we kick off BioPharm America 2012, the most productive partnering event on the East Coast!

BioPharm America is a great way to build off of your partnering momentum from the 2012 BIO International Convention and make the most of the last quarter of 2012 so that you can head into 2013 on top of the game.

At BioPharm America you will have the chance to meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships.

Last year there were:

• 2,550 one-to-one meetings
• 950+ delegates
• 760 licensing opportunities
• 82 company presentations
• 34 countries represented
• 22 exhibitors
• 21 workshops and panels.

The growing number of firms attending this year’s meeting include: Actelion, Alkermes, Alexion, Amgen, AstraZeneca, Atlas Ventures, Biogen Idec, Bristol-Myers Squibb, Celgene, CMEA Capital, Epizyme, Genzyme, HealthCare Ventures, Ironwood, Johnson & Johnson, Merck Research Venture Fund, NovoNordisk, Sanofi Oncology, Shire HGT, Takeda, United Therapeutics, and many more!

Register today to begin scheduling your partnering meetings.

JUST ANNOUNCED: This year’s conference will kick off with the 2012 Fierce 15 announcement, followed by a keynote address from David Meeker, Genzyme’s President & CEO. The program continues with a robust lineup of speakers discussing today’s important industry challenges. You can see the full program here.

You can register at www.ebdgroup.com/bpa/registration/index.php or contact Christina Kirsch at ckirsch@ebdgroup.com or +1 760 930 0500. MassBio members save $200 on registration, just mention you’re a MassBio member in the registration comments field.

See you at BioPharm America 2012!

Bob Coughlin
President & CEO, MassBio